Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Phase II Study to Investigate DSA Rebound in Patients With a Positive Crossmatch, Made Transplantable With Imlifidase

NCT05049850 is registered in ClinicalTrials.gov with Hansa Biopharma AB as lead sponsor.

NCT NCT05049850
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05049850 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Phase II Study to Investigate DSA Rebound in Patients With a Positive Crossmatch, Made Transplantable With Imlifidase
Lead sponsor
Hansa Biopharma AB
Phase
Phase 2
Overall status
Terminated
Start date
December 16, 2022
Completion date
May 8, 2024
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplantation in highly sensitized patients